Cargando…

Anti-cancer drug characterisation using a human cell line panel representing defined types of drug resistance.

Differential drug response in a human cell line panel representing defined types of cytotoxic drug resistance was measured using the non-clonogenic fluorometric microculture cytotoxicity assay (FMCA). In total 37 drugs were analysed; eight topoisomerase II inhibitors, eight anti-metabolites, eight a...

Descripción completa

Detalles Bibliográficos
Autores principales: Dhar, S., Nygren, P., Csoka, K., Botling, J., Nilsson, K., Larsson, R.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1996
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2074735/
https://www.ncbi.nlm.nih.gov/pubmed/8826854
_version_ 1782138031523758080
author Dhar, S.
Nygren, P.
Csoka, K.
Botling, J.
Nilsson, K.
Larsson, R.
author_facet Dhar, S.
Nygren, P.
Csoka, K.
Botling, J.
Nilsson, K.
Larsson, R.
author_sort Dhar, S.
collection PubMed
description Differential drug response in a human cell line panel representing defined types of cytotoxic drug resistance was measured using the non-clonogenic fluorometric microculture cytotoxicity assay (FMCA). In total 37 drugs were analysed; eight topoisomerase II inhibitors, eight anti-metabolites, eight alkylating agents, eight tubulin-active agents and five compounds with other or unknown mechanisms of action, including one topoisomerase I inhibitor. Correlation analysis of log IC50 values obtained from the panel showed a high degree of similarity among the drugs with a similar mechanism of action. The mean percentage of mechanistically similar drugs included among the ten highest correlations, when each drug was compared with the remaining data set, was 100%, 92%, 88% and 52% for the topoisomerase II inhibitors, alkylators, tubulinactive agents and anti-metabolites respectively. Classification of drugs into the four categories representing different mechanisms of action using a probabilistic neural network (PNN) analysis resulted in 29 (91%) correct predictions. The results indicate the feasibility of using a limited number of cell lines for prediction of mechanism of action of anti-cancer drugs. The present approach may be well suited for initial classification and evaluation of novel anti-cancer drugs and as a potential tool to guide lead compound optimisation. IMAGES:
format Text
id pubmed-2074735
institution National Center for Biotechnology Information
language English
publishDate 1996
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-20747352009-09-10 Anti-cancer drug characterisation using a human cell line panel representing defined types of drug resistance. Dhar, S. Nygren, P. Csoka, K. Botling, J. Nilsson, K. Larsson, R. Br J Cancer Research Article Differential drug response in a human cell line panel representing defined types of cytotoxic drug resistance was measured using the non-clonogenic fluorometric microculture cytotoxicity assay (FMCA). In total 37 drugs were analysed; eight topoisomerase II inhibitors, eight anti-metabolites, eight alkylating agents, eight tubulin-active agents and five compounds with other or unknown mechanisms of action, including one topoisomerase I inhibitor. Correlation analysis of log IC50 values obtained from the panel showed a high degree of similarity among the drugs with a similar mechanism of action. The mean percentage of mechanistically similar drugs included among the ten highest correlations, when each drug was compared with the remaining data set, was 100%, 92%, 88% and 52% for the topoisomerase II inhibitors, alkylators, tubulinactive agents and anti-metabolites respectively. Classification of drugs into the four categories representing different mechanisms of action using a probabilistic neural network (PNN) analysis resulted in 29 (91%) correct predictions. The results indicate the feasibility of using a limited number of cell lines for prediction of mechanism of action of anti-cancer drugs. The present approach may be well suited for initial classification and evaluation of novel anti-cancer drugs and as a potential tool to guide lead compound optimisation. IMAGES: Nature Publishing Group 1996-09 /pmc/articles/PMC2074735/ /pubmed/8826854 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Dhar, S.
Nygren, P.
Csoka, K.
Botling, J.
Nilsson, K.
Larsson, R.
Anti-cancer drug characterisation using a human cell line panel representing defined types of drug resistance.
title Anti-cancer drug characterisation using a human cell line panel representing defined types of drug resistance.
title_full Anti-cancer drug characterisation using a human cell line panel representing defined types of drug resistance.
title_fullStr Anti-cancer drug characterisation using a human cell line panel representing defined types of drug resistance.
title_full_unstemmed Anti-cancer drug characterisation using a human cell line panel representing defined types of drug resistance.
title_short Anti-cancer drug characterisation using a human cell line panel representing defined types of drug resistance.
title_sort anti-cancer drug characterisation using a human cell line panel representing defined types of drug resistance.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2074735/
https://www.ncbi.nlm.nih.gov/pubmed/8826854
work_keys_str_mv AT dhars anticancerdrugcharacterisationusingahumancelllinepanelrepresentingdefinedtypesofdrugresistance
AT nygrenp anticancerdrugcharacterisationusingahumancelllinepanelrepresentingdefinedtypesofdrugresistance
AT csokak anticancerdrugcharacterisationusingahumancelllinepanelrepresentingdefinedtypesofdrugresistance
AT botlingj anticancerdrugcharacterisationusingahumancelllinepanelrepresentingdefinedtypesofdrugresistance
AT nilssonk anticancerdrugcharacterisationusingahumancelllinepanelrepresentingdefinedtypesofdrugresistance
AT larssonr anticancerdrugcharacterisationusingahumancelllinepanelrepresentingdefinedtypesofdrugresistance